Generalized Anxiety Disorder 7-Item Scale (GAD-7) 

The GAD-7 is a 7-item, self-report screening tool that scores generalized anxiety symptom severity over the prior two weeks on a 0-21 scale, with established bands of minimal, mild, moderate, and severe. It takes 2-5 minutes to complete and is widely used to screen for and track anxiety, including as a comorbidity in post-concussion and TBI care.

What the GAD-7 Measures

The GAD-7 asks patients to rate how often, over the past two weeks, they have been bothered by seven core anxiety symptoms — feeling nervous or on edge, being unable to stop or control worrying, worrying excessively about different things, trouble relaxing, restlessness, irritability, and a sense of impending danger or dread. Each item is rated on a 0-3 scale (not at all, several days, more than half the days, nearly every day), and the seven item scores are summed for a total ranging from 0 to 21.

The instrument was developed and validated by Spitzer and colleagues as a brief primary-care screening tool for generalized anxiety disorder, and it has since become one of the most widely used anxiety measures across primary care, psychiatry, and specialty medicine, including neurology and sports medicine settings that manage concussion and TBI patients.

Administration Time

The GAD-7 is designed for rapid administration: most patients complete it in 2 to 5 minutes, whether on paper, verbally, or through a digital/patient-portal format. Because it is brief and self-explanatory, it is well suited to repeated, between-visit administration for symptom tracking rather than a one-time intake screen alone.

Scoring and Interpretation

Total scores range from 0 to 21 and are commonly grouped into four severity bands:

• 0-4: Minimal anxiety
• 5-9: Mild anxiety
• 10-14: Moderate anxiety
• 15-21: Severe anxiety

A total score of 10 or higher is commonly cited as having good sensitivity and specificity for identifying generalized anxiety disorder in validation studies, and some protocols use a lower threshold of 8 as a broader screen for any anxiety disorder. As with any self-report screening instrument, the GAD-7 is not a standalone diagnostic tool — an elevated score should prompt clinical interview and, where appropriate, diagnostic evaluation rather than functioning as a diagnosis on its own. Clinicians should also weigh score trends over time (serial administrations) alongside any single score, since a single time point can be influenced by transient stressors.

Clinical Use Case

In general practice, the GAD-7 is used both as an initial anxiety screen and as a tool for monitoring symptom trajectory during treatment. In concussion and TBI care specifically, anxiety is a common comorbid or post-injury symptom, and the GAD-7 is frequently paired with a depression screen such as the PHQ-9 and a trauma screen such as the PCL-5 to build a fuller picture of the mental-health burden that can accompany or follow a concussion. Serial GAD-7 scores collected between visits can help a clinician see whether anxiety symptoms are improving, plateauing, or worsening as physical and cognitive recovery progresses, which is directly relevant to return-to-play, return-to-work, and return-to-learn decisions.

CPT Code for Administering the GAD-7

When the GAD-7 is billed as a standalone brief screening instrument (rather than as part of a larger neuropsychological battery), it is typically captured under 96127 — brief emotional/behavioral assessment with a standardized instrument, including scoring and documentation. When the GAD-7 is delivered and scored through an automated, patient-facing digital format outside of an E/M visit, some practices instead bill under 96146 (automated administration and scoring). Coverage and the appropriate code depend on how and by whom the instrument is administered, and on payer-specific policy — see CPT 96132 and CPT 96136 for related codes used when the GAD-7 is embedded in a broader battery interpreted by a physician or qualified health professional.

Because GAD-7 data collected between visits also documents ongoing monitoring of a chronic behavioral-health symptom, it is one of the instruments that can support Remote Therapeutic Monitoring documentation under codes like 98978 when built into a structured between-visit monitoring program — see our guide on RTM for cognitive-behavioral monitoring for how the pieces fit together.

Where the GAD-7 Sits in the Kavera Protocol

The GAD-7 is one of the mood/anxiety screens included in Kavera's assessment battery, delivered as part of the Mental Health module and commonly co-administered alongside it in the Concussion module, since anxiety is a frequent post-injury comorbidity. Because Kavera delivers the GAD-7 between visits on a recurring cadence, it generates a longitudinal severity trend rather than a single snapshot — data that supports both clinical decision-making and the documentation needs of RTM and behavioral-health screening billing.

How Kavera Handles This

The GAD-7 goes out between visits in the Mental Health module, usually alongside the PHQ-9. Scores are banded automatically and flagged when they cross 10 or jump from the last administration. Patients on the guided support tool for mild anxiety can't advance a session until you approve the last one, so the GAD-7 trend and the treatment are reviewed together. Self-Serve practices run this with their own staff. On Managed, Juliet Mott's team runs it and bills it under your credentials.

FAQ

Is the GAD-7 diagnostic for generalized anxiety disorder?

No. The GAD-7 is a screening and severity-tracking tool. A score of 10 or higher is commonly associated with good sensitivity and specificity for GAD in validation research, but a formal diagnosis requires clinical interview and, where indicated, further evaluation.

How often should the GAD-7 be administered?

There is no single fixed interval; many protocols use it at intake and then repeat it periodically (for example, every visit or on a set between-visit schedule) to track whether anxiety symptoms are trending up, down, or holding steady.

Can the GAD-7 be billed on its own?

It can be captured under 96127 when administered and scored as a brief standalone standardized instrument, or under 96146 when delivered through an automated/computerized format outside an E/M visit. The applicable code depends on administration method and payer policy — see CPT 96132 for the interpretation code used when the GAD-7 is part of a larger battery.

Does the GAD-7 replace a full psychiatric evaluation?

No. It is a brief screen intended to flag elevated anxiety symptoms and support ongoing monitoring, not to replace a comprehensive psychiatric or psychological evaluation.

Why is anxiety screening relevant to concussion care?

Anxiety is a common comorbid or post-injury symptom after concussion and TBI, and it can interact with recovery timelines, sleep, and cognitive symptoms — see Screening for Depression After TBI and Managing Persistent Post-Concussive Symptoms for related clinical context.

Sources: Spitzer et al., 2006, GAD-7 validation — Archives of Internal Medicine (opens in a new tab); CMS — Psychological and Neuropsychological Tests Billing and Coding (opens in a new tab); AAPC — CPT 96116-96146 code range (opens in a new tab)

This page provides general educational information about a clinical assessment instrument and related billing codes. It is not clinical, coding, or compliance advice, and does not guarantee reimbursement. Verify current coverage and documentation requirements with CMS, your Medicare Administrative Contractor, and each payer before billing.